Active Ingredient History

NOW
  • Now
Etanercept, sold under the brand name Enbrel among others, is a biologic medical product that is used to treat autoimmune diseases by interfering with tumor necrosis factor (TNF), a soluble inflammatory cytokine, by acting as a TNF inhibitor. It has U.S. Food and Drug Administration (FDA) approval to treat rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Tumor necrosis factor alpha (TNFα) is the "master regulator" of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF-alpha.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$399.5700 - $1484.6801

Australia

$770.1753
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

benepali | cd120b | enbrel | entanercept | erelzi | etanercept | etanercept (genetical recombination) | etanercept-szzs | hitanercept | l04ab01 | p75 | p80 tnf-alpha receptor | rhu tnfr:fc | tnf-r2 | tnfr:fc | tnfr-immunoadhesin | tnr 001 | tnr-001 | tumor necrosis factor receptor 2 | tumor necrosis factor receptor superfamily member 1b precursor | tumor necrosis factor receptor type ii

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue